Methotrexate (MTX) therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams34942
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1138
- Available Online
- View Pamphlet
Your health care provider feels that treatment with methotrexate (meth-oh-TREX-ate) might help your Crohn’s disease or ulcerative colitis. These are both types of inflammatory bowel disease (IBD). This pamphlet explains what methotrexate (MTX) is, how well it works, side effects of MTX, who should not take MTX, and precautions. Instructions for injecting MTX are given.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (13 p.) : digital, PDF file
- Specialty
- Gastrointestinal System
- Medications
- Abstract
- Your health care provider feels that treatment with methotrexate (meth-oh-TREX-ate) might help your Crohn’s disease or ulcerative colitis. These are both types of inflammatory bowel disease (IBD). This pamphlet explains what methotrexate (MTX) is, how well it works, side effects of MTX, who should not take MTX, and precautions. Instructions for injecting MTX are given.
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1138
Corticosteroid therapy in inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35480
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1546
- Available Online
- View Pamphlet
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Alternate Title
- Corticosteroid therapy in IBD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Prednisone
- Subjects (LCSH)
- Inflammatory bowel diseases
- Prednisone
- Specialty
- Gastrointestinal System
- Medications
- Abstract
- Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Notes
- This pamphlet replaced pamphlet 1139, Prednisone Therapy.
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1546
Azathioprine and Mercaptopurine Therapy
https://libcat.nshealth.ca/en/permalink/chpams35565
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1079
- Available Online
- View Pamphlet
This pamphlet will help you decide if azathioprine (Imuran®) or mercaptopurine therapy is right for you. The pamphlet explains what azathioprine (AZA) and mercaptopurine (6-MP) are, how well they work, as well as serious and less serious side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (6 p.): digital, PDF file
- Subjects (MeSH)
- Immunosuppressive Agents
- Azathioprine
- Mercaptopurine
- Subjects (LCSH)
- Immunosuppressive agents
- Specialty
- Medications
- Abstract
- This pamphlet will help you decide if azathioprine (Imuran®) or mercaptopurine therapy is right for you. The pamphlet explains what azathioprine (AZA) and mercaptopurine (6-MP) are, how well they work, as well as serious and less serious side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
- Notes
- Previous title: Azathioprine (Imuran) therapy
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1079
Risankizumab (Skyrizi®) therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams38191
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 2345
- Available Online
- View Pamphlet
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Gastrointestinal System
- Medications
- Abstract
- Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 2345
